MoonLake Immunotherapeutics (MLTX) Debt to Equity (2021)
MoonLake Immunotherapeutics (MLTX) recorded quarterly Debt to Equity of -$1.29 in Q4 2021.
MoonLake Immunotherapeutics (MLTX) Debt to Equity (2021) Analysis & Trends
MoonLake Immunotherapeutics' Debt to Equity history runs 1 years deep, the most recent figure standing at -$1.29 for Q4 2021.
- In Q4 2021, Debt to Equity changed N/A year-over-year to -$1.29; the TTM figure through Dec 2021 stood at -$1.29 (changed N/A YoY), while the FY2021 annual figure was -$1.29, changed N/A from the prior year.
- Debt to Equity was -$1.29 for Q4 2021 at MoonLake Immunotherapeutics.
- In the past five years, Debt to Equity ranged from a high of -$1.29 in Q4 2021 to a low of -$1.29 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | MoonLake Immunotherapeutics | 1.25 Bn | 888.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -1.29 |